Back to search results

Beta Blocker Dialyzability on Cardiovascular Outcomes in Kidney Disease

This study is looking at whether metoprolol succinate or carvedilol is better for patients with end-stage kidney disease (ESKD) who are on hemodialysis. Researchers want to see if metoprolol succinate, which can be removed by dialysis, leads to better heart health outcomes compared to carvedilol, which is not removed by dialysis. You might be able to join if you are 18 or older, on hemodialysis, and already receiving certain beta blockers through the VA pharmacy. The main goal is to track how long it takes for a major cardiovascular event to happen, with an average follow-up of three years. The study aims to enroll 2540 participants, but its current status is unclear.

Study design
This is a point-of-care randomized controlled trial comparing two different beta blockers. It plans to enroll 2540 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from randomization until a major cardiovascular event occurs, with an average follow-up of 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05931276

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

Recruiting
PHASE3Ages 18+InterventionalTreatment
VA Office of Research and Development
~2,540 participants
Updated 2026-01-09 on ClinicalTrials.gov
What's tested:Metoprolol SuccinateCarvedilol

At a glance

Recruiting sites
7 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to major cardiovascular event
Measured over Randomization to time to event; average follow-up 3 years

Conditions

End-Stage Kidney Disease
End-Stage Renal Disease

Explore related trials

Cardiovascular DisorderChronic Renal Failure

Where it's being run

8 sites across 8 states
California1
Florida1
Georgia1
Iowa1
Massachusetts1
Minnesota1
Nebraska1
New Mexico1

Study leadership

  • Areef Ishani, MD MS · STUDY_CHAIR · Minneapolis VA Health Care System, Minneapolis, MN

Who to contact

Christopher M Donnelly
[email protected]
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

On hemodialysis
Received one of the following beta blockers through the VA pharmacy: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, bisoprolol

Exclusion

Impaired decision-making capacity
Patients not receiving carvedilol who have a history of asthma
known hypersensitivity to any component of either drug
Provider unwilling to sign a new medication order for a randomized patient
No surrogate consent will be allowed

What this trial measures

  • Time to major cardiovascular eventRandomization to time to event; average follow-up 3 years

    The Primary outcome measure will be time to a non-fatal adverse cardiovascular event, defined as a composite outcome comprised of the first occurrence after randomization of any of the following: myocardial infarction, stroke, or hospitalization for heart failure, and all-cause mortality